Clinical trials: Invasive Carcinoma
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00053209
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 121 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014144
- Testing
- gefitinib
- Where
- 95 sites in United States
- Volunteers
- 31 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma
Minimally Invasive Sweet Esophagectomy for Patients With Siewert Type II Adenocarcinoma of the Esophagogastric Junction
Of the esophagogastric junction adenocarcinoma (AEG) is a 5 cm region of adenocarcinoma of the esophagus and stomach. Due to the special anatomical location, the biological behavior of esophageal cancer and gastric cancer are not…
- Trial name
- NCT02741778
- Testing
- Minimally invasive group, Open group
- Volunteers
- 120 people
- Sponsor
- Anhui Provincial Hospital
Urothelial Carcinoma, Bladder Cancer
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Upon successful screening and registration, enrollment to a cohort will begin. If DLT criteria are exceeded in a cohort, that cohort will close and will not proceed to Phase 2 of the study.
- Trial name
- ADAPT-BLADDER (NCT03317158)
- Testing
- Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG)
- Where
- 9 sites in United States
- Volunteers
- 186 people
- Sponsor
- Noah Hahn, M.D.
Breast Cancer
Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation during surgery may be an effective treatment for breast cancer.
- Trial name
- NRR (NCT00182728)
- Testing
- surgery, therapy, radiation therapy
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Superficial Bladder Cancer, Bladder Cancer
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index…
- Trial name
- TROJAN (NCT03379909)
- Testing
- Metformin
- Where
- 3 sites in Netherlands
- Volunteers
- 49 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Urinary Bladder Neoplasms
The Bladder Instillation Comparison Study
To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.
- Trial name
- BIC (NCT02695771)
- Testing
- Mitomycin C, Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Corewell Health West
Muscle Invasive Upper Tract Urothelial Carcinoma
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual…
- Trial name
- NCT05595408
- Testing
- Adjuvant chemotherapy, adjuvant immunotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- RenJi Hospital
Non-Muscle Invasive Bladder Neoplasms
Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
The purpose of this pre-approval access program is to provide access to TAR-200 prior to its marketing authorization for the treatment of participant(s) with high-risk non-muscle invasive bladder cancer (HR-NMIBC).
- Trial name
- NCT06877676
- Testing
- TAR-200
- Sponsor
- Janssen Research & Development, LLC
Invasive Breast Cancer
EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast
Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world.
- Trial name
- NCT05703815
- Volunteers
- 40 people
- Sponsor
- Sohag University
Invasive Breast Cancer, Cavitation
Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Blood perfusion insufficiency and hypoxia are the main causes of drug resistance to chemotherapy in breast cancer. Increasing blood perfusion can improve drug delivery.
- Conditions
- Invasive Breast Cancer, Cavitation, Perfusion
- Trial name
- NCT06158217
- Testing
- ultrasound combined with microbubbles
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Kidney Tumors Treated With Minimally Invasive Surgery
Partial Nephrectomy in Low Pressure
The main objective is to prospectively assess the impact of low insufflation pressure using AirSeal system (7mm Hg) during RAPN on post-operative patient pain (main location and intensity), 24 hours after surgery.
- Trial name
- P-NeLoP (NCT05404685)
- Testing
- Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy, Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy
- Where
- 15 sites in France
- Volunteers
- 280 people
- Sponsor
- University Hospital, Bordeaux
Squamous Cell Esophageal Carcinoma
Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal Cancer
The primary objective is to compare neo-adjuvant chemoradiotherapy followed by Mckeown Minimally Invasive Esophagectomy (MIE) Versus Mckeown MIE, pure radical chemoradiotherapy in terms of the overall survival time (OS) in…
- Trial name
- NACRFMIE (NCT02188615)
- Testing
- Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE, Cisplatin, Mckeown MIE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chengchu Zhu
Breast Cancer, Neuroendocrine Tumors
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Prospective phase 2a clinical trial to demonstrate proof-of-concept for simultaneous hyperpolarized [1-13C]pyruvate and 18F-FDG for positron emission tomography (PET) and MRS (magnetic resonance spectroscopy) in a PET/MR scanner…
- Conditions
- Breast Cancer, Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic
- Trial name
- NCT05396118
- Testing
- 18F-FDG, Injection of hyperpolarized [1-13C]Pyruvate, PET/MR/MRS/MRSI scanning
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Bladder Cancer, Urothelial Carcinoma Bladder
Bladder Cancer Adjuvant Radiotherapy Trial
Aim and objectives: This trial aims to evaluate the role of adjuvant radiotherapy following chemotherapy in patients with high-risk features on histo-pathology after radical surgery for transitional cell carcinoma of urinary…
- Trial name
- BART (NCT02951325)
- Testing
- Adjuvant RT
- Where
- India
- Volunteers
- 153 people
- Sponsor
- Tata Memorial Centre
Estrogen Receptor Negative, HER2/Neu Negative
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT02445391
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 1,024 sites in United States, South Africa
- Volunteers
- 415 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer - Ductal Carcinoma in Situ (DCIS), Breast Cancer
Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer
This single-center prospective study will evaluate the feasibility and safety of endoscopic nipple-sparing mastectomy (E-NSM) performed through a single axillary incision in selected women with breast cancer undergoing…
- Trial name
- Mini-B (NCT07507890)
- Testing
- Endoscopic Nipple-Sparing Mastectomy (E-NSM)
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Breast Cancer, Invasive Breast Cancer
Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients
This study aims to investigate the role of a mobile health app, Outcomes4Me, in the navigation of care for people with breast cancer.
- Conditions
- Breast Cancer, Invasive Breast Cancer, Metastatic Breast Cancer, Breast Carcinoma
- Trial name
- FIONA (NCT04262518)
- Testing
- Outcomes4Me Mobile App
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Outcomes4Me
NMIBC
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall.
- Trial name
- HIGCrecur (NCT06889623)
- Testing
- Immediate postoperative chemotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Changhai Hospital
Breast Cancer, Dermatologic Complications
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
RATIONALE: Steroid therapy, such as mometasone furoate, may prevent radiation dermatitis caused by radiation therapy. It is not yet known whether mometasone furoate is more effective than a placebo in preventing radiation…
- Conditions
- Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
- Trial name
- NCT00438659
- Testing
- mometasone furoate
- Where
- 189 sites in United States
- Volunteers
- 176 people
- Sponsor
- North Central Cancer Treatment Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.